Skip to content

The PURE Report

Independent industry benchmark of patient and HCP satisfaction, utilization, and evolving needs across patient support programs

Enabling pharma and biotech companies to deliver an enhanced patient and HCP experience.

The PURE Report is the only standardized, annual, and independent assessment of HCP satisfaction with pharmaceutical companies’ patient support services and their industry rankings against competition. 

Recognize HCP preferences, ways of working, and trends for how they want to engage with pharma support programs.

Identify areas of opportunity to focus efforts in areas of greatest customer and organizational need.

Secure appropriate resourcing by providing leadership insight into why investments are required.

Know how you compare to other programs to support investments and strategic planning.

Ensure long-term impact as the annual report allows for ongoing benchmarking supporting investments & decision making.

Overview of the PURE Report

The PURE Report is the only independent study co-created with HCPs for measuring HCP satisfaction.

The PURE Report is the only independent study co-created with HCPs for measuring HCP satisfaction.

Inside the PURE Report

HCP Service Preference
Communication with HCPs
Pharma Company Ranking

What Users of the PURE Report Say:

“Wow, the results are very insightful! We did not know how we perform relative to our competition, but are not surprised since it reconfirms indications we had from other research. This will be very helpful moving forward.”
Associate Director, Patient Services
Fortune 500 Pharmaceuticals/Biotech
“The arrival of the report is very timely. We are beginning our brand planning and the PURE Report is a great support to guide us for what to address in the upcoming year.”
DIRECTOR, PATIENT REIMBURSEMENT
Fortune 500 Pharmaceuticals/Biotech
“My concern with most research is to ensure the findings are actionable. One of the things I like about the PURE Report is that it is filled with actionable findings for us to consider as we improve our program.”
BRAND DIRECTOR
Fortune 500 Pharmaceuticals/Biotech
“This reports has so much information in it. Some of the outputs are surprising while others confirm beliefs I had since before. Nevertheless, it is a tremendous resource for us to use.”
EXEC DIRECTOR, MARKET ACCESS
Fortune 500 Pharmaceuticals/Biotech